We tested an inactivated egg-grown whole virus influenza A/H5N1 vaccine candidate developed by the Institute of Vaccines and Medical Biologicals (IVAC), a state-run vaccine manufacturer in Vietnam, in a Phase 1, placebo controlled, double blinded, randomized trial. The vaccine was adjuvanted with aluminum hydroxide. The trial enrolled 75 subjects who were randomized to receive two injections of one of the following: low-dose of vaccine (7.5 mcg HA), high-dose of vaccine (15 mcg HA), or placebo. The vaccine candidate was well tolerated with minimal local reactogenicity consisting of mild, shortlived injection site pain and/or tenderness. No systemic reactogenicity was observed other than transient low-grade fever in about 13% of the subjects and no unsolicited adverse events were attributable to product administration. Immune responses were assessed at baseline and after the first and second dose by hemagglutination inhibition (HAI) and microneutralization (MN) assays, with 72% of the high-dose and 68% of the low-dose vaccine recipients presenting a P4-fold response in the HAI assay and 72% of the high-dose and 61% of the low-dose vaccine recipients exhibiting a P4-fold response in the MN assay. These promising results support further development. ClinicalTrials.gov number NCT02171819, June 20, 2014.
Introduction
The 2009 influenza A/H1N1 pandemic illustrates the unpredictability of the influenza virus and supports a call for significant preparedness efforts across the globe to anticipate new threats. The effects of an influenza pandemic are likely to be greatest in resource-limited countries where individuals may be more susceptible to severe outcomes of influenza due to underlying nutritional deficiencies and concomitant illness, poorer sanitary conditions, limited access to health care, and the lack of widespread use of vaccines for influenza as well as against common causes of bacterial pneumonia [1] . During the influenza A/H1N1 pandemic, vaccine availability was limited in industrialized countries and was significantly delayed in low-resource countries.
Since 1996, highly pathogenic influenza A/H5N1 avian viruses have caused widespread outbreaks in poultry with high mortality as well as sporadic, severe, and fatal disease in humans [2] . From 2003 through 2016, the World Health Organization (WHO) confirmed 850 human cases of influenza A/H5N1 influenza infection, with 449 deaths [3] . Southeast Asian countries, including Vietnam, have been disproportionately affected by influenza A/H5N1 accounting for 48.2% of all confirmed influenza A/H5N1 cases reported during that period. Influenza A/H5N1 infection in animals is now thought to be endemic in the region [4] . By May 2016, Vietnam had reported 125 confirmed human cases, with 62 deaths [5] .
Influenza vaccination is considered the optimal approach to prevent infection and/or limit severe illness. Vaccination could target individuals that may be exposed to zoonotic transmission, or to the general population or segments of it, depending on vaccine availability, in the event of a pandemic threat. If an influenza A/ H5N1 pandemic were to occur, the vaccine demand to control it would be enormous. There is a substantial need for local development, production, and stockpiling of influenza A/H5N1 and other pandemic influenza vaccines (such as A/H7N9) in Vietnam for pandemic preparedness. To date, however, no influenza A/H5N1 vaccine has been licensed in Vietnam. To address this, the Vietnam Institute of Vaccines and Medical Biologicals (IVAC) has manufactured pandemic influenza vaccine candidates, including influenza A/H1N1, A/H5N1, and A/H7N9, as well as a trivalent seasonal vaccine candidate under guidance from the Vietnam Ministry of Health (MOH). IVAC has tested the A/H1N1 vaccine candidate in clinical trials [6] . We present in this manuscript the results of testing IVAC's influenza A/H5N1 vaccine candidate in a Phase 1 clinical trial to initiate the assessment of its safety and immunogenicity.
Methods

Study design and implementation
Clinical testing of the influenza A/H5N1 vaccine candidate was conducted as a Phase 1, double blinded, randomized, placebocontrolled study at a community clinic in the Ben Luc District, Long An Province, Vietnam. The primary objective of the study was to evaluate the safety profile of two intramuscular doses of the vaccine, the secondary objective was to evaluate its immunogenicity. Seventy-five healthy male and female adults, 18-30 years of age, were enrolled into the trial to receive two doses of vaccine or placebo three weeks apart. Subjects were randomized to one of the following three treatment allocations: 32 subjects to 7.5 mcg/dose vaccine (low-dose), 31 subjects to 15 mcg/dose vaccine (highdose), and 12 subjects to placebo. This sample size was selected to enable at least 30 evaluable subjects in each of the groups to receive active vaccine. The study was double blinded to study subjects, investigators, and the sponsor until the clinical and laboratory data were completed, fully reviewed, and the database was locked.
In order to be included in the study, subjects had to be healthy (from medical history and physical exam), aged 18-30 years; willing to provide written informed consent; capable and willing to complete diary cards; and willing to return for all visits. Females were asked to utilize reliable birth control measures. Exclusion criteria included: participation in another clinical trial involving receipt of any non-study vaccine or immunoglobulins within four weeks of enrollment; current or recent acute illness with or without fever; chronic administration of immunosuppressants; history of asthma; or hypersensitivity after previous administration of any vaccine, to any of the vaccine components, including chicken or egg protein, food, or environmental allergens. Injections of study product were staggered to allow for an initial safety evaluation of a sentinel cohort of 19 subjects, which preceded the remainder of the study group by approximately two to three weeks. Once all of the volunteers in the sentinel group received a dose of study vaccine and safety information for seven days post-vaccination was available, the data were reviewed by a safety monitoring committee composed of independent experts not associated with the study, who provided a recommendation to vaccinate the rest of the study cohort.
Rationale for study design
After consultation with a Product Development Advisory Group that includes members from WHO, IVAC, PATH, the US Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA), and independent consultants expert in influenza vaccine development, IVAC chose to evaluate two dose levels of vaccine, 7.5 and 15 mcg hemagglutinin (HA) content per 0.5 mL dose given 21 days apart. The doses were chosen because pandemic monovalent vaccines for influenza A/H5N1 strains are known to require a higher HA content than what was used for influenza A/H1N1 vaccines during the recent pandemic or used for other human influenza strains, and at the same time to identify an effective dose lower than the high-doses used with other H5N1 products (doses of 30-45 mcg have been used by Sanofi, Microgen, or CSL).
Investigational product
The study product was inactivated, whole virion, monovalent influenza A/H5N1 vaccine candidate (IVAC/Nha Trang). The vaccine was produced in embryonated eggs, inactivated with formalin, and formulated with aluminum hydroxide 0.6 mg/0.5 mL. The following two different doses of vaccine were tested: 7.5 mcg (lowdose) and 15 mcg (high-dose) per 0.5 mL. IVACFLU-A/H5N1 was filled in single dose vials. Each 0.5 mL dose may have contained residual amounts of formaldehyde (not more than 0.02%) and sucrose (not more than 2.0%). Placebo consisting of phosphate buffered saline (PBS) was also manufactured by IVAC. A 0.5 mL singledose vial with a pH of 7.2 was used per injection.
Two lots of IVACFLU-A/H5N1 vaccine and one lot of placebo were used in the study. They were examined for quality control by the National Institute of Control Vaccine and Medical Biologicals and were granted the certificate of quality that met the requirements on physical properties, pH, aluminum concentration, protein concentration, potency, identity, general safety, endotoxin, and sterility.
Study vaccine and placebo were labeled at IVAC in compliance with MOH's drug labeling regulations before they were shipped to Pasteur Institute-Ho Chi Minh City (PI-HCMC) for storage and to the study site at the Ben Luc District Health Center for use. To blind the vaccinator and study subjects, a nurse with no other study duties was responsible for withdrawing study product from vials according to the randomization schedule. The aluminum hydroxide adjuvant in the vaccine gave it a slightly different appearance from the placebo, therefore, in order to maintain the blinding, the nurse masked the syringe before handing it over to the vaccinator by covering the original label with an identical study label containing only the study product code of each subject.
Assigning subjects to study groups
Each subject was assigned a unique screening number after signing the screening informed consent. Once the subject was considered to be eligible and he or she signed the consent for the vaccine portion of the study, the subject was randomized by assigning a unique subject identification number sequentially in ascending order from the randomization schedule. The mechanics of the randomization was the responsibility of a PATH staff scientist not otherwise involved with the trial. A permuted block randomization method with the block size of 19 was used to computer generate a randomization schedule with a pre-specified ratio of 8:8:3 (lowdose vaccine: high-dose vaccine: placebo). The randomization schedule was produced using SAS computer software and consisted of the subject identification number and the corresponding treatment assignment. The first 19 subjects enrolled were treated as a ''sentinel" cohort before the remaining 57 subjects were enrolled. For both, the sentinel cohort and the rest of the cohort the pre-specified randomization ratio of 8:8:3 was used.
Safety assessments
The safety profile of IVACFLU-A/H5N1 was evaluated for the occurrence of: (1) reactions within 60 min of administration as observed by study staff or reported by subjects; (2) solicited local and systemic reactions commonly associated with intramuscular vaccination occurring within seven days of dosing (solicited adverse events [AEs]); (3) other AEs observed over the three weeks period after each vaccination; and (4) serious adverse events (SAEs) occurring within three weeks of receipt of any dose. AEs and SAEs were recorded according to standard ICH definitions [7] . These evaluations included clinical findings observed by the physician or reported by the subject on diary cards (completed each day for seven days post-vaccination), as well as abnormal laboratory findings from blood specimens collected on Days 7 and 28. The on-site study principal investigator made all determinations of potential relatedness of the observed AEs to the study product.
Immunogenicity assessments
Immune responses to IVACFLU-A/H5N1 were evaluated in serum samples obtained before the first vaccination (baseline), and three weeks after each vaccination, on Days 21 and 42. Qualified hemagglutination inhibition (HAI) and microneutralization (MN) assays were conducted at the PI-HCMC laboratories following WHO and Centers for Disease Control and Prevention recommended protocols [8, 9] .
The HAI assay used influenza A/H5N1 virus (NIBRG-14) as the antigen and was performed in duplicate wells of twofold serial dilutions of serum. The serum HAI titer is the reciprocal of the serum dilution in the last well with complete hemagglutination inhibition [8] .
The MN assay determines the titer of neutralizing antibodies against influenza A/H5N1. The assay was performed in MDCK cell cultures in duplicate wells at twofold serial dilutions of serum. The neutralizing antibody titer is the reciprocal of the serum dilution resulting in 50% drop in viral antigen (nucleoprotein) as detected by ELISA [9] . The geometric mean titers (GMT) and corresponding confidence intervals were based on a log 10 scale. Exact confidence intervals were reported for all proportion estimates.
Statistical considerations
Categorical data were summarized by number and percentage of subjects falling within each group; continuous variables are summarized by descriptive statistics including mean, standard error or deviation, median, minimum, and maximum (a SAS program was used). Point estimates and exact 95% confidence intervals for the proportions meeting immunogenicity endpoints were calculated for the vaccine and placebo groups and the combined vaccine group; in addition, point estimates and 95% confidence intervals about the differences in response rates (vaccine -placebo) were calculated using the Wilson Score Method.
Results
Disposition of subjects
One hundred and thirty-three subjects were screened at Visit 1.
One subject was a screen failure at Visit 1 and inadvertently screened at Visit 2, but was never vaccinated. Another screened subject withdrew before the first vaccination. Seventy-five subjects, aged 18-30 years old, were enrolled and received two injections of vaccine or placebo 21 days apart. All 75 subjects received the two study product doses and completed the study. Vaccinations took place between June and July 2014. The last subject visit was conducted on August 24, 2014 and the study completed with database lock on November 19, 2014.
Demographics and other baseline characteristics
Demographic and baseline characteristics are summarized in Table 1 . Overall, the mean age in the three treatment groups was 23.6 years (range [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] 
Vaccine safety
Immediate reactions: No immediate (within 60 min) postvaccination reactions were reported after any dose of study product.
Solicited AEs (local and systemic reactogenicity): Solicited AEs occurring more than 60 min following vaccination doses through seven days post-vaccination are summarized in Table 2 . After both vaccinations combined, 26 (83.9%) subjects in the low-dose vaccine group, 26 (81.3%) in the high-dose vaccine group, and 4 (33.3%) in the placebo group had at least one solicited AE.
Pain when touching the injection site or pain after injection were the only reported local reactogenicity. After both vaccinations combined, at least one solicited local AE was observed in 25 (80.6%) subjects in the low-dose vaccine group, 24 (75.0%) in the high-dose vaccine group, and 3 (25.0%) in the placebo group. More local reactions were observed after the first vaccination than after the second vaccination. After the first vaccination, 25 (80.6%) subjects in the low-dose vaccine group, 23 (71.9%) in the high-dose vaccine group, and 1 (8.3%) in the placebo group had at least one solicited local AE. After the second vaccination, 13 (41.9%) subjects in the low-dose vaccine group, 17 (53.1%) in the high-dose vaccine group, and 2 (16.7%) in the placebo group had at least one solicited local AE. All local AEs were mild and short-lived regardless of postvaccination period or treatment group.
After both vaccinations combined, at least one event of systemic reactogenicity was reported by 13 (41.9%) subjects in the low-dose vaccine group, 14 (43.8%) in the high-dose vaccine group, and 4 (33.3%) in the placebo group. The most common systemic events were headache (10 or 15.9% of subjects in the combined vaccine Table 1 Demographics and baseline characteristics. ) subjects in the combined vaccine groups were feverish (as defined as having temperature above 37.7°C and above or feeling feverish), but no subjects who received placebo were feverish. Twelve (38.7%) subjects in the low-dose vaccine group, 12 (37.5%) in the high-dose vaccine group, and 4 (33.3%) in the placebo group had at least one mild systemic solicited AEs (systemic reactogenicity) after either the first or second dose (combined). One subject (3.2%) in the low-dose vaccine group and two subjects (6.3%) in the high-dose vaccine group had a moderate AE of headache. More subjects experienced systemic reactogenicity after the first vaccination than after the second vaccination for both vaccine groups. Unsolicited AEs: Unsolicited AEs were defined as safety events occurring anytime post-vaccination through three weeks after the second vaccination. A summary of the unsolicited AEs is presented in Table 3 .
Overall, 12 (38.7%) subjects in the low-dose vaccine group, 12 (37.5%) in the high-dose vaccine group, and 4 (33.3%) in the placebo group had at least one unsolicited AE during the study. The distribution of unsolicited AEs was similar across treatment groups and post-vaccination periods, with a couple of exceptions. Five subjects (7.9%) receiving the vaccine had AEs related to increase in laboratory measurements or vital signs, while no subjects receiving a placebo had these AEs.
In the low-dose vaccine group, 8 (25.8%) subjects had at least one mild unsolicited AE, 3 (9.7%) had a moderate AE, and 1 (3.2%) had a severe AE. In the high-dose vaccine group, 11 (34.4%) subjects had a mild AE and 1 (3.1%) had a moderate AE. In the placebo group, 4 (33.3%) subjects had a mild AE. Across treatment groups, more subjects experienced mild AEs after the first vaccination than after the second vaccination. Three vaccinated subjects had moderate bilirubin increases after the second vaccination (all in the low-dose group), but all returned to mild promptly and none was considered to be clinically significant. The single severe unsolicited AE occurred in a subject who experienced a left clavicle bone fracture deemed unrelated to vaccination. No SAEs were reported in the study and no AEs led to study discontinuation.
Immunogenicity
Immune responses were measured at baseline (prevaccination) and 21 days after each vaccine dose (Day 21 and Day 42). The proportion of subjects achieving an HAI titer P1:40 after each dose and those achieving a P4-fold rise in HAI titer are presented in Tables 4A and B, respectively. Seven of 31 (22.6%) subjects receiving the low-dose of vaccine and 9 of 32 (28.1%) subjects receiving the high-dose achieved an HAI titer P1:40 after first vaccination. The number increased to 13 (41.9%) and 18 (56.3%) subjects after the second vaccination for low-and high-dose vaccine, respectively. No placebo subjects reported HAI titer P1:10 at any visit. A significant difference in response rates was observed after first vaccination for high-dose vaccine (95% CI: 0.82, 45.37) and after second vaccination for both low and high vaccine doses compared to placebo. No significant difference in response rates were observed between the low-dose and the high-dose after either vaccination.
The proportion of subjects achieving a P4-fold rise in HAI antibody titer between doses (baseline to post-dose 1 and baseline to post-dose 2) is presented in Table 4B . Such responses were observed in 35.5% of low-dose recipients and 37.5% of high-dose recipients after the first vaccination. The corresponding seroresponse rate between baseline and post-second dose were 67.7% and 71.9% for low-dose and high-dose vaccine recipients, respectively. Table 5 summarizes the GMT and GMT ratio (GMTR) for HAI antibodies. No HAI antibodies were detected in any of the 75 participants at baseline. GMT rose to 12.8 (low-dose) and 11.9 (highdose) after the first vaccination and to 24.5 (low-dose) and 27.1 (high-dose) after the second vaccination. The corresponding GMTR rises with respect to placebo were 2.56 and 2.38 after the first vaccination, and 4.89 and 5.42 after the second vaccination for low and high-doses, respectively. The GMTs and GMTRs in the vaccine groups were significantly higher (i.e., the lower bound of the 95% confidence interval for the GMT ratio or GMTR ratio >1.0) than placebo, but no difference in GMTs or GMTRs was found between the low-dose and high-dose vaccine groups at either dose.
In the MN assay, a P4-fold rise was observed from baseline to post-first vaccination in 5 of 31 (16.1%) and 7 of 32 (21.9%) subjects for low-dose and high-dose vaccine, respectively. Similar P4-fold rise between baseline and second vaccination were seen 19 out Table 3 Participants reporting unsolicited AEs by grade/system/organ/class and preferred term after first and second vaccinations combined. of 31 subjects (61.3%) after low vaccine dose, and in 23 out of 32 (71.9%) after the high-dose (Table 6 ). Neutralization GMTs after the first vaccination with the lowdose or high-dose were similar (9.4), and rose to 21.9 for the low-dose and to 23.3 for the high-dose after the second vaccination (Table 7) . No neutralization was detected in baseline sera from any of the participants or in post-vaccination sera from the placebo recipients. GMTRs for neutralizing antibodies with respect to Notes: N -Total number of subjects in each group; n -Total number of subjects meeting the event. a 95% confidence interval for single proportion is calculated using Exact Clopper-Pearson method. b The 95% two sided confidence intervals for the difference in Immune response rates are constructed based on Newcombe-Wilson score method done for Per protocol population. Table 5 GMT for HAI antibody and GMTRs. N -Total number of subjects in each group; n -the number of subjects with antibody titers. Geometric Mean titer (GMT) and 95% CIs are calculated by taking the anti-natural log of the means and 95% CI of the log transformed titers. Confidence intervals are constructed using t distribution on the natural log transformed titer values and then back transformed into the original values. a Ratio of GMT = GMT for test/GMT for control.
placebo were 1.9 for both the low-dose and high-dose after first vaccination and 4.4 (low-dose) and 4.7 (high-dose) after second vaccination. Table 8 presents a detailed analysis of HAI and MN responses at the individual participant level. Taking into account the two assays employed, the overall P4-fold seroresponse rates were 68% for the low-dose recipients (i.e., 22 of the 31 participants presented either an HAI or a neutralization response), and 72% for the high-dose recipients. Further, if a twofold change were to be considered a seroresponse, all but three of the low-dose and one of the highdose responses presented evidence of immune priming (post hoc analysis). None of the placebo recipients presented a P2-fold response.
Discussion
Since the first human case of influenza A/H5N1 detected twenty years ago, over 800 human cases with a fatality rate of over 50% have been recorded worldwide. Continuous reintroduction and spread of the virus in poultry in several Asian countries has had a devastating economic impact. While transmission to humans is rare, mutations that can allow efficient transmission between humans could result in a pandemic of enormous consequences.
More than two dozen inactivated influenza A/H5N1 vaccines have been produced around the world. For a few of them, stockpiles are available in a few resource-rich countries. Some resource-limited countries are receiving technical and logistical support from WHO to develop their own vaccines for stockpiling or for use in high-risk populations. Vietnam is one such country where the MOH-affiliated vaccine manufacturer, IVAC, has received support to develop the influenza A/H5N1 vaccine candidate tested in this study. Two injections of two different dose levels (7.5 and 15 mcg) of the vaccine or placebo were administered to 75 subjects in a blinded study. The vaccine was well tolerated with no serious or severe local or systemic reactogenicity at either dose tested. No immediate post-vaccination reactions were reported and the solicited reactions observed within the seven days postvaccination were all mild and well tolerated, consisting primarily of spontaneous pain at the injection site or pain when touching it. No induration, redness, or edema were observed. Few solicited systemic events were recorded over the week after each vaccination. Unsolicited AEs were similar in frequency and severity among vaccine and placebo recipients, and in no case were deemed to be related to administration of the investigational product. Of all the unsolicited AEs observed, only three were more than mild in severity (one in a subject in the low-dose vaccine group and two in subjects in the high-dose group). None of the events observed was N -Total number of subjects in each group; n -the number of subjects with non-missing antibody titer results at both, pre-and post-vaccination. Geometric Mean titer (GMT) and 95% CIs are calculated by taking the anti-natural log of the means and 95% CI of the log transformed pre-and post-vaccination titers. The CIs are constructed using t distribution on the natural log transformed values of the antibody titer, the values are then transformed into the original values. Titer below the lowest limit of quantification (i.e. below the starting dilution of assay reported as ''<10") was set to half that limit (i.e., 10/2 = 5).
clinically significant or led to discontinued study participation. The safety data observed justifies continuing the development of this vaccine candidate in larger populations. The immunological assays conducted on post-vaccination sera demonstrated rates and levels of immune response similar to those of other influenza A/H5N1 inactivated vaccines. Overall, about 70% of the recipients presented a fourfold or greater seroresponse in the HAI assay, with slightly more frequent responses to the high-dose, but without a demonstrable statistically significant difference. Similar response rates were observed in the neutralization assay employed. None of the participants had demonstrable preexisting antibodies to influenza A/H5N1 virus and none of the placebo recipients developed a seroresponse. Given the latter observation, an ad hoc analysis was conducted that showed that all but one participant in the high-dose group, and all but three participants in the low-dose group would have been considered vaccine responders if a twofold rise in titer from baseline was used as the criterion for immunogenicity. Furthermore, such responses were already observed in about half of the subjects following the first vaccine dose, attesting to the ability of the vaccine to prime the immune system in naïve subjects.
The frequency and magnitude of responses was lower than those observed with seasonal inactivated influenza vaccines (see DD Anh et al. in this issue of Vaccine), an observation that has been made for all other H5 and H7 avian influenza vaccines tested in clinical trials [10, 11] . As this was anticipated, and following the lead from other studies, the vaccine consisted of a whole virus preparation. Whole virus vaccines have indeed the potential to be more immunogenic than split-virus or subunit vaccines in previously unvaccinated populations [12, 13] . Moreover, and again, following the lead from prior studies the vaccine was adjuvanted with aluminum hydroxide [14, 15] .
While recognizing that significant variability occurs across different laboratories in the use of HAI and microneutralization assays to evaluate influenza vaccines, our vaccine compares favorably to similar vaccines developed/tested in the United States [16] , using a 15 mcg dose of a H5 subunit vaccine, and are similar to the ones reported for aluminum hydroxide adjuvanted vaccines manufactured in Japan [17] , Russia [18] , China [19] , and Thailand [20] . Higher immune response rates and titers have been observed with the use of ASO3 adjuvant [21] or with MF59 adjuvant [22, 23] . The safety and immunogenicity results of this Phase 1 study are very promising and support further development of the product towards licensure. Before moving into a pivotal Phase 3 study, however, we decided to investigate the potential that a higher vaccine dose (30 mcg) may be more immunogenic than the current doses tested, in a study that is now ongoing.
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